2-Bromo-3-methyl-5-nitropyridine | CAS:23132-21-0

We serve 2-Bromo-3-methyl-5-nitropyridine CAS:23132-21-0 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
2-Bromo-3-methyl-5-nitropyridine

Chemical Name:2-Bromo-3-methyl-5-nitropyridine
CAS.NO:23132-21-0
Synonyms:2-Bromo-3-methyl-5-nitropyridine
2-bromo-3-methyl-5-nitro-pyridine
6-Brom-5-methyl-3-nitropyridin
2-Bromo-5-nitro-3-picoline
Molecular Formula:C6H5BrN2O2
Molecular Weight:217.02000
 
Physical and Chemical Properties:
Density:
Melting point:57-58ºC
Boiling point:ºC
Flash point:ºC
Index of Refraction:
 
Specification:
Appearance:Yellow to brown crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Organic synthesis intermediate



Contact us for information like 2-Bromo-3-methyl-5-nitropyridine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Bromo-5-nitro-3-picoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Bromo-5-nitro-3-picoline Use and application,2-Bromo-5-nitro-3-picoline technical grade,usp/ep/jp grade.


Related News: Vietnam recently barred almost all flights to and from mainland China, Hong Kong and Macau until May 1, according to the United States Federal Aviation Administration.flucytosine manufacturer The API can be directly formulated, and the intermediate can only be used to synthesize the next product. Only through the intermediate can the API be manufactured.4-bromobutan-1-ol supplier China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.2-(2,5-dioxopyrrolidin-1-yloxy)-1,3-dimethyl-3,4,5,6-tetrahydropyrimidin-1-ium hexafluorophosphate vendor China will use its national drug bulk-buy scheme to lower the price of drugs currently sold at higher prices compared with other markets, it said in an official statement.However, in the long run, as the bulk API market continues to fall, more and more companies will transition to specialty API companies, and competition will intensify in the future.